[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470314":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":93,"collaborators":25,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":25,"enrollmentInfo":105,"targetDuration":25,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":25,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Vejle Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fish oil","ACTIVE_COMPARATOR","4 capsules containing n-3 poly unsaturated fatty acids (EPA and DHA) with a total concentration of 3 g per day.\n\n4 capsules per day for 8 months",[13],"Dietary Supplement: Fish oil",{"label":15,"type":16,"description":17,"interventionNames":18},"Corn oil","PLACEBO_COMPARATOR","4 capsules containing n-6 poly unsaturated fatty acids in a total concentration of 2 g per day.\n\n4 capsules per day for 8 months.\n\nCorn oil is regularly used in the kitchen and the daily dose in the study is the equivalent of adding an extra spoon of food oil when cooking. It has no known effect on the parameters we want to examine.",[19],"Dietary Supplement: Corn oil",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Fish oil containing poly unsaturated fatty acids.",[9],null,{"type":22,"name":15,"description":15,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Lise Ventzel, MD PHD","medical doctor at Vejle Hospital, University Hospital of southern Denmark","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Malene Nielsen, MD.","CONTACT","+45 26823726","Malene.Nielsen6@rsyd.dk",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Karin Larsen","+ 45","Karin.Larsen1@rsyd.dk",[44,59,70,81],{"facility":45,"status":46,"city":47,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Department of Oncology, AAUH","RECRUITING","Aalborg","Denmark","DK",{"type":51,"coordinates":52},"Point",[53,54],9.9187,57.048,{"lat":54,"lon":53},[57],{"name":58,"role":36,"phone":25,"phoneExt":25,"email":25},"Laurids Østergaard Poulsen",{"facility":60,"status":46,"city":61,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Department of Oncology, AUH","Aarhus",{"type":51,"coordinates":63},[64,65],10.21076,56.15674,{"lat":65,"lon":64},[68],{"name":69,"role":36,"phone":25,"phoneExt":25,"email":25},"Christian Hviid",{"facility":71,"status":46,"city":72,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Department of Oncology","Sønderborg",{"type":51,"coordinates":74},[75,76],9.78917,54.90896,{"lat":76,"lon":75},[79],{"name":80,"role":36,"phone":25,"phoneExt":25,"email":25},"Stinne Husum",{"facility":82,"status":46,"city":83,"state":25,"zip":25,"country":48,"countryCode":49,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Department of Oncology, Vejle Hospital","Vejle",{"type":51,"coordinates":85},[86,87],9.5357,55.70927,{"lat":87,"lon":86},[90],{"name":91,"role":36,"phone":92,"phoneExt":25,"email":38},"Malene Nielsen, MD","+4526823726",{"type":94,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100470314","prevention-of-oxaliplatin-induced-nerve-damage-in-the-bodys-extremities-100470314",false,"NCT05404230","Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities","Prevention of Oxaliplatin-induced Peripheral Neuropathy - a Randomized Controlled Trial","OxaNeuro","Inclusion Criteria:\n\n* Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.\n* ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.\n* Written and orally informed informed consent\n\nExclusion Criteria:\n\n* Inability to speak, read, and understand Danish.\n* Previous treatment with neurotoxic chemotherapy.\n* Neurological (including neuropathy) or psychiatric disorders, diabetes or other significant medical conditions.\n* Alcohol or drug abuse.\n* Sensory disturbances in the feet\n* Spinal stenosis.\n* Vascular disease (Fontaine grade II or more).\n* Known allergy to fish, fish oil or corn oil\n* Fertile patients not willing to use effective methods of contraception during treatment or abstinence.\n* Daily intake of oil supplements and not willing to stop during the trial period.\n* Lack of consent to skin biopsy","ALL","18 Years",{"count":106,"type":107},120,"ESTIMATED","INTERVENTIONAL",[110],"NA","The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.",[113,114],"Peripheral Neuropathy","Colorectal Cancer","2026-05-18",{"date":117,"type":118},"2026-05-19","ACTUAL",{"date":120,"type":118},"2022-07-15",{"date":122,"type":107},"2028-12",{"name":5,"class":6},4]